Drug intelligence / Profile preview

INV-002

Development stage: Phase 3
Lead developer: Inventera
Modality: Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

INV-002, developed by Inventera, is a high-performance nano-MRI contrast agent. It is specifically designed for use in MR arthrography, a medical imaging technique used to visualize joint structures. The drug candidate utilizes a proprietary nanostructure platform technology to enhance magnetic resonance imaging, aiding in the precise diagnosis of joint-related conditions.

Brand names: NEMO-103NEMO103NEMO 103
Other names: INV-002INV002INV 002

Beyond the preview

Go deeper on INV-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INV-002.

Explore the full profile